Serum Biomarkers to Differentiate Benign and Malignant Mammographic Lesions

Journal of the American College of Surgeons

Volumn 204, Issue 5, 2007, Pages 1065-1071

  Shin, Susanna ^a   Cazares, Lisa ^a   Schneider, Heather ^a   Mitchell, Shamina ^a   Laronga, Christine ^a   Semmes, O John ^a   Perry, Roger R ^a   Drake, Richard R ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CATION EXCHANGE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEVICE; DIAGNOSTIC ACCURACY; FEMALE; GENE CLUSTER; GENETIC ALGORITHM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INSTRUMENTATION; MAMMOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; STATISTICAL SIGNIFICANCE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ALGORITHMS; BIOPSY; BLOOD PROTEINS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34247479930     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.01.036     Document Type: Article

References (31)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. American College of Radiology. Breast Imaging Reporting and Data System (BIRADS). 3rd ed. (1998), American College of Radiology, Reston, VA
3. Obenauer S., Hermann K.P., and Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol 15 (2005) 1027-1036
4. Lazarus E., Mainiero M.B., Schepps B., et al. BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. Radiology 239 (2006) 385-391
5. Vlahou A., Laronga C., Wilson L., et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 4 (2003) 203-209
6. Laronga C, Becker S, Watson P, et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003-2004;19:229-238.
7. Pusztai L., Gregory B.W., Baggerly K.A., et al. Pharmacoproteomic analysis of pre- and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer. Cancer 100 (2004) 1814-1822
8. Becker S., Cazares L.H., Watson P., et al. Surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11 (2004) 907-914
9. Li J., Zhang Z., Rosenzweig J., et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 (2002) 1296-1304
10. Bertucci F., Birnbaum D., and Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 5 (2006) 1772-1786
11. Li J., Orlandi R., White C.N., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51 (2005) 2229-2235
12. de Noo M.E., Deelder A., van der Werff M., et al. MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 29 (2006) 501-506
13. Goncalves A., Estemi B., Bertucci F., et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25 (2006) 981-989
14. Villanueva J., Philip J., Entenberg D., et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76 (2004) 1560-1570
15. Conrads T.P., Hood B.L., Issaq H.J., et al. Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn 8 (2004) 77-85
16. Wright G.L. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2 (2002) 549-563
17. Pusch W., and Kostrzewa M. Application of MALDI-TOF mass spectrometry in screening and diagnostic research. Curr Pharm Des 11 (2005) 2577-2591
18. Baggerly K.A., Morris J.S., and Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20 (2004) 777-785
19. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97 (2005) 315-319
20. Sorace J.M., and Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4 (2003) 24
21. Hu J., Coombes K.R., Morris J.S., et al. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 3 (2005) 322-331
22. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nature Rev Cancer 5 (2005) 142-149
23. Semmes O.J., Feng Z., Adam B.L., et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51 (2005) 102-112
24. Fung E.T., Yip T.T., Lomas L., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115 (2005) 783-789
25. Overall C.M., and Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 25 (2006) 69-75
26. Ming Zhou M., Prieto D.A., Lucas D.A., et al. Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry. J Proteome Res 5 (2006) 2207-2216
27. Lee I.N., Chen C.H., Sheu J.C., et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6 (2006) 2865-2873
28. Malik G., Ward M.D., Gupta S.K., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 11 (2005) 1073-1085
29. Paradis V., Degos F., Dargere D., et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41 (2005) 40-47
30. Semmes O.J. The "omics" haystack: defining sources of sample bias in expression profiling. Clin Chem 51 (2005) 1571-1572
31. Drake R.R., Schwegler E.E., Malik G., et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 5 (2006) 1957-1967